Clinical trial · Observational
Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site
NCT07325864CI-TRIAL-00100432recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
investigate the molecular differences between primitive lung cancer and the metastatic site.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer (Diagnosis) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site in patient diagnosed with NSCLC
- description
- To investigate the molecular differences between primitive lung cancer and the metastatic site.
Primary outcomes (1)
- measure
- To investigate the molecular differences between primitive lung cancer and the metastatic site.
- timeFrame
- From baseline to 18 months
- description
- Tumoral DNA will be extracted from the formalin-fixed paraffin-embedded (FFPE) block containing the highest percentage of tumor cells, with macrodissection, if necessary, to obtain at least 30% of tumor cells. DNA was extracted from FFPE samples. Next-generation sequencing (NGS) analysis will be performed as previously described. Gene amplification is defined by a coverage mean superior to 3SD.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients aged ≥18 years fit enough to tolerate the surgical operation; * the operative risk is considered low based on respiratory reserve and cardiac assessment; * the patient has clearly expressed willingness to adhere; * availability of pathological material for tumor DNA extraction and NGS execution. Exclusion Criteria: * Women of childbearing age, pregnant or breastfeeding, or intending to become pregnant during the study. * Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation. * Recent or ongoing severe or clinically significant infection.
References
Publications (0)
Data not yet available
No reference posted for this study.